| Jamie Gleich, | |
|
9 Lacrue Ave, Glen Mills, PA 19342-1062 | |
| (800) 578-7906 | |
| (800) 878-5497 |
| Full Name | Jamie Gleich |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 9 Lacrue Ave, Glen Mills, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104024702 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jamie Gleich, 846 W Bradley Pl # 1, Chicago, IL 60613-3903 Ph: () - | Jamie Gleich, 9 Lacrue Ave, Glen Mills, PA 19342-1062 Ph: (800) 578-7906 |
News Archive
Cigarette smokers who were treated for cerebral aneurysms with coil embolization (blocking of a blood vessel) are at greater risk of developing another aneurysm, say neurological surgeons at Jefferson Hospital for Neuroscience in Philadelphia in the first-known study of its kind.
Unemployed doorman Alexis Rodriguez says he almost became ill when he received a $44.8 million bill from the Bronx-Lebanon Hospital Center. Rodriguez was hospitalized last spring with pneumonia and was afraid the bill was legitimate. His actual bill stood at $300.
A recent study by researchers at the University of British Columbia (B.C.) shows that the benefits of continuing the COVID-19 vaccine of front-line workers with the AstraZeneca vaccine outweigh the increased risk of prothrombotic thrombocytopenia.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
› Verified 3 days ago
Haley L Kypers, SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 300 Franklin Dr, Glen Mills, PA 19342 Phone: 610-936-6514 | |
Carly Gross, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Lacrue Ave, Glen Mills, PA 19342 Phone: 800-578-7906 Fax: 800-878-5497 | |
Stephanie D. Phelps, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Lacrue Ave, Glen Mills, PA 19342 Phone: 800-578-7906 Fax: 800-878-5497 | |
Tanya Srouji, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Lacrue Ave, Glen Mills, PA 19342 Phone: 800-578-7906 Fax: 800-878-5497 | |
Amy Hartford-jacobs, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Maris Grove Way, Glen Mills, PA 19342 Phone: 610-387-4622 | |
Lynn Gabos, CCC/SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 8 Thomas Speakman Dr, Glen Mills, PA 19342 Phone: 610-613-1498 | |
Goldy Levy, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Lacrue Ave, Glen Mills, PA 19342 Phone: 800-578-7906 Fax: 800-878-5497 |